BioNTech to Acquire CureVac in $1.25 Billion All-Stock Transaction

Deal News | Jun 23, 2025 | Loyens & Loeff

BioNTech to Acquire CureVac in $1.25 Billion All-Stock Transaction

BioNTech has announced the acquisition of CureVac in an all-stock transaction valued at approximately $1.25 billion. Under the terms of the Purchase Agreement, CureVac shareholders will receive approximately $5.46 in BioNTech ADSs per share. This acquisition is set to cement BioNTech's position in the field of mRNA-based cancer immunotherapy by integrating CureVac's technology and research capabilities. The deal marks a significant milestone in BioNTech's oncology strategy. Loyens & Loeff advised on various aspects of the transaction including corporate, tax, and capital markets. Post-acquisition, CureVac and its subsidiaries will undergo corporate restructuring, transferring full ownership to BioNTech. BioNTech, known for its pioneering immunotherapy technology, aims to leverage CureVac's mRNA advancements to further its cancer and serious disease treatment pipelines. Founded in 2000, CureVac has been at the forefront of mRNA technology, developing new treatments in oncology and infectious diseases.

Sectors

  • Biotechnology
  • Pharmaceuticals

Geography

  • Germany – Both BioNTech and CureVac are based in Germany, making it a central geography for the transaction.

Industry

  • Biotechnology – The article revolves around advancements in biotechnology, specifically in mRNA technologies which both BioNTech and CureVac specialize in.
  • Pharmaceuticals – The focus on cancer immunotherapy candidates and the development of transformative medicines places the article firmly within the pharmaceuticals sector.

Financials

  • 1.25 billion USD – Implied aggregate equity value for CureVac based on the transaction terms.
  • 5.46 USD – Value in BioNTech ADSs offered for each CureVac share.

Participants

NameRoleTypeDescription
BioNTechBidding CompanyCompanyA global leader in immunotherapy, focusing on novel therapies for cancer and serious diseases.
CureVacTarget CompanyCompanyA multinational biotech innovator in mRNA technology for human medicine applications, particularly in oncology and infectious diseases.
Loyens & LoeffLegal AdvisorCompanyProvided legal and tax advisory services on the corporate, tax, employment, and capital markets aspects of the transaction.